Pharmaceutical Business review

Vertex prices public offer at $32

The company expects to raise $320 million in aggregate gross proceeds from the common stock offering.

Merrill Lynch & Company is acting as the sole book-runner, with Cowen and Company acting as co-manager, for the offering.